AMLX (Amylyx Pharmaceuticals) Total Liabilities: $20.44 Mil (As of Mar. 2026)


AMLX Amylyx Pharmaceuticals Inc AMLX
33 GF Score
Price $17.79
! 3 Warning Signs
View Full Analysis

What is Amylyx Pharmaceuticals Total Liabilities?

Amylyx Pharmaceuticals AMLX +2.01% 33 Total Liabilities is $20.44 Mil as of Mar. 2026. GuruFocus rates AMLX with a GF Score™ of 33/100. The stock has 3 warning signs investors should review.

Amylyx Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was $20.44 Mil.

Amylyx Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2025 ($30.75 Mil) to Dec. 2025 ($27.39 Mil) and declined from Dec. 2025 ($27.39 Mil) to Mar. 2026 ($20.44 Mil).

Amylyx Pharmaceuticals's annual Total Liabilities declined from Dec. 2023 ($84.02 Mil) to Dec. 2024 ($28.87 Mil) and declined from Dec. 2024 ($28.87 Mil) to Dec. 2025 ($27.39 Mil).

Amylyx Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Amylyx Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amylyx Pharmaceuticals Total Liabilities Chart

Amylyx Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 256.78 50.85 84.02 28.87 27.39

Amylyx Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.26 26.72 30.75 27.39 20.44
AMLX
33GF Score
Amylyx Pharmaceuticals Inc AMLX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amylyx Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Amylyx Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=22.688+(4.698+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=27.39

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=332.645-305.259
=27.39

Amylyx Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=15.966+(4.476+8.8817841970013E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=20.44

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=293.603-273.161
=20.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $20.44 Mil mean?
Amylyx Pharmaceuticals (AMLX) has a Total Liabilities of $20.44 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Amylyx Pharmaceuticals and its competitors.
Is Amylyx Pharmaceuticals' Total Liabilities too high?
Amylyx Pharmaceuticals' current Total Liabilities is $20.44 Mil. Overall, Amylyx Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Amylyx Pharmaceuticals' Total Liabilities compare to PRGO and ANIP?
Amylyx Pharmaceuticals' Total Liabilities of $20.44 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Amylyx Pharmaceuticals and its competitors. Amylyx Pharmaceuticals's current Total Liabilities is $20.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amylyx Pharmaceuticals stock overvalued right now?
Amylyx Pharmaceuticals (AMLX) has a current Total Liabilities of $20.44 Mil. The current Total Liabilities is $20.44 Mil. Amylyx Pharmaceuticals' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Amylyx Pharmaceuticals (AMLX), the current Total Liabilities is $20.44 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Amylyx Pharmaceuticals Business Description

Address 55 Cambridge Parkway, Suite 6W, Cambridge, MA, USA, 02142
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
33GF Score

Get the complete analysis for AMLX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.79
Price